Ning Shaoxia, a professor at Xiamen University, and Zhu Jiang, an associate professor at Scripps Institute, recently published a study in Nature Newsletter, revealing many "secrets" of hepatitis E vaccine. In 20 12, the world's first hepatitis e vaccine "yikangning" went on the market. The vaccine was jointly developed by Xiamen University National Infectious Disease Diagnostic Reagents and Vaccine Engineering Research Center and Yangshengtang Beijing Wan Tai Biopharmaceutical Co., Ltd., and Wan Tai Bio (hereinafter referred to as Yangshengtang) is the only hepatitis E vaccine listed at present.

The current clinical trial data and animal experimental results show that hepatitis E vaccine has the potential to protect different genotypes of hepatitis E virus infection. But how can hepatitis E vaccine trigger antibody reaction after it enters human body? Why can these antibodies prevent the infection of other genotypes of hepatitis E virus? For many years, these are unsolved scientific problems.

These results reveal the source of protective antibodies induced by hepatitis E vaccine for the first time, and confirm that antibodies induced by hepatitis E vaccine have cross-broad-spectrum protective effects, which will help the global promotion of hepatitis E vaccine. There is no specific medicine, and vaccine is an important preventive measure. Hepatitis E is a kind of viral hepatitis caused by hepatitis E virus (HEV) infection, which ranks fifth in the viral hepatitis family. The clinical symptoms are similar to those of hepatitis A, which are generally characterized by flu-like precursor symptoms such as fever and nausea, accompanied by jaundice, anorexia and hepatomegaly.

The World Health Organization estimates that 20 million people worldwide are infected with HEV virus every year, and about 3.3 million of them have symptoms of hepatitis E. Among high-risk groups (pregnant women and patients with chronic liver disease), the mortality rate of hepatitis E is as high as 20% to 30%, which has become an important public health problem in the world. In China, the number of cases and deaths of hepatitis E exceeds that of hepatitis A every year.

Three doses of hepatitis E vaccine are needed in the whole process, and each dose of hepatitis E vaccine has targeted immune response, antibody production and antibody evolution and maturity. "Zheng said. Under difficult circumstances, researchers creatively used single B cell research technology, low deviation antibody group and traditional serological analysis methods to study small samples of hepatitis E vaccination, and dynamically revealed the generation, development and maturity of protective antibodies in the process of human vaccination from three levels: single cell, cell group and serology.